A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór - zaawansowany lub przerzutowy rak płuca (typ niepłaskonaborowy)
- •Specjalny gen w komórkach raka (mutacja KRAS G12C)
- •Wcześniejsze leczenie - co najmniej dwie poprzednie terapie bez pełnego efektu
- •Próbka tkanki guza dostępna do badań
- •Osoby z HIV muszą mieć kontrolowaną infekcję przy pomocy leków przeciwretrowirusowych
✗ Disqualifies
- •Drobnokomórkowy rak płuca (inny typ)
- •Poważne problemy z funkcją płuc
- •Przerzuty do mózgu aktywnie rosnące
- •Zmiany oczu - poważne problemy z rogówką lub bardzo suche oczy
- •Szczepienia na żywe wirusy w ciągu ostatnich 30 dni
- •Poważne zaburzenia serca lub naczyń krwionośnych
- •Niekontrolowana choroba zapalna jelit
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (25)
Clermont Oncology Center ( Site 0041)
Clermont, United States
University of Illinois Hospital & Health Sciences System ( Site 0044)
Chicago, United States
Providence Portland Medical Center ( Site 0043)
Portland, United States
Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)
Portland, United States
Hospital São Lucas da PUCRS ( Site 0283)
Porto Alegre, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)
Barretos, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)
São José do Rio Preto, Brazil
Hospital Paulistano ( Site 0280)
São Paulo, Brazil
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)
Santiago, Chile
FALP ( Site 0161)
Santiago, Chile
Bradfordhill ( Site 0160)
Santiago, Chile
Guangdong Provincial People s Hospital ( Site 0300)
Guangzhou, China
UniversitaetsklInikum Tuebingen ( Site 0192)
Tübingen, Germany
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)
Athens, Greece
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)
Athens, Greece
Queen Mary Hospital ( Site 0230)
Hong Kong, Hong Kong
Hong Kong United Oncology Centre ( Site 0232)
Jordan, Hong Kong
Prince of Wales Hospital ( Site 0231)
Shatin, Hong Kong
Shaare Zedek Medical Center ( Site 0186)
Jerusalem, Israel
Sheba Medical Center ( Site 0180)
Ramat Gan, Israel
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0176)
Meldola, Italy
Severance Hospital, Yonsei University Health System ( Site 0080)
Seoul, South Korea
Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
Hospitalet, Spain
Hospital Clinic de Barcelona ( Site 0092)
Barcelona, Spain
Hospital Universitario Virgen Macarena ( Site 0093)
Seville, Spain
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.